A Scalable and GMP-Ready Downstream Process for Lentiviral Vectors

Thank you - Your Download is Available Below

A Scalable and GMP-Ready Downstream Process for Lentiviral Vectors

PDF | 2.3 MB

A Scalable and GMP-Ready Downstream Process for Lentiviral Vectors

The use of CIM^® monoliths is becoming more prevalent in gene therapy and viral vaccine production. This case study explores the integration of CIMmultus^® QA monolith-based anion exchange chromatography (AEX) in lentiviral downstream purification and the optimization of the manufacturing platform at NecstGen.

Key outcomes:

85% TU recovery and a significant reduction in impurities,
improved recovery and purity of lentiviral vectors,
reduced manufacturing expenses.

Clear form data

Please Complete the Form

First Name *

Last Name *

Email *

Phone Number *

Company *

Job Title *

Address *

Country *

Postal Code *

I would like to sign up for newsletters from Sartorius (Sartorius AG and its affiliated companies) based of my personal interests.
I can revoke my consent at any time with effect for the future by sending an e-mail to unsubscribe@sartorius.com or by clicking on the "unsubscribe" link in e-mails I have received.

* These fields are required Information on the use of your data can be found in our privacy policy

Thank you - Your Download is Available Below

A Scalable and GMP-Ready Downstream Process for Lentiviral Vectors

A Scalable and GMP-Ready Downstream Process for Lentiviral Vectors

Please Complete the Form

Complete Form to Access the File